On June 22, 2015, the United States District Court for the Southern District of California appointed KSF as sole lead counsel in In re Orexigen Therapeutics, Inc., Securities Litigation, 15cv540 L (KSC), stating,”[t]he Court has reviewed the firm’s resume, See Abadou Decl., Exh. D, ECF No. 37-6, and is satisfied that the lead plaintiff has made a reasonable choice of counsel. The Kahn Swick & Foti firm has extensive experience in the prosecution of securities class actions and it appears that it will adequately represent the interests of all class members.”